Inhibrx Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in La Jolla, California and currently employs 166 full-time employees. The company went IPO on 2024-05-28. Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.

Industry: Biological Products, (No Diagnostic Substances) Peers: Adicet Bio Inc Agenus Inc Altimmune Inc Cullinan Therapeutics Inc HilleVax, Inc. IDEAYA Biosciences Inc Nurix Therapeutics Inc Nkarta Inc Vera Therapeutics, Inc